- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05753930
Imlifidase prima del trapianto di rene in bambini altamente sensibilizzati (DINKY)
Uno studio multicentrico a braccio singolo per valutare l'efficacia e la sicurezza di Imlifidase in bambini altamente sensibilizzati (1-17 anni) che ricevono un trapianto di rene con crossmatch positivo rispetto a un donatore vivente o deceduto convertito in negativo dopo il trattamento con Imlifidase
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).
The main questions it aims to answer are:
- Does imlifidase treatment result in crossmatch conversion that enables transplantation?
- How is the function of the transplanted kidney?
The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
After being informed about the study and potential risks, all patients giving written informed consent will undergo pre-screening to determine eligibility for study entry.
The trial will include highly sensitised ESRD paediatric patients (1-17 years). The patients have previously undergone desensitization unsuccessfully or have an anti-HLA antibody status deemed too difficult to make a successful desensitization using other experimental methods.
A screening visit will take place when an organ offer has been placed for a final check of the patients' eligibility for study participation.
All patients included in the trial will be desensitized with imlifidase to convert the positive XM to negative and then transplanted with either a kidney from a deceased donor (DD) or a living donor (LD).
Patients will be hospitalised in accordance with the normal routines for transplanted patients at each clinic.
Following transplantation, the patients will receive induction therapies, rejection prophylaxis, and maintenance immunosuppressive therapies.
The patients will be closely monitored for any signs of antibody-mediated rejections (AMRs).
The duration of the interventional trial period after an organ has been offered will be 6 months for each patient. The trial includes a follow-up part to collect long-term efficacy and safety data up to 5 years after the transplantation.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Central Contact
- Numero di telefono: +46 46 16 56 70
- Email: clinicalstudyinfo@hansabiopharma.com
Luoghi di studio
-
-
-
Helsinki, Finlandia, 00290
- Ritirato
- HUS, Helsinki University Hospital
-
-
-
-
-
Paris, Francia, 75019
- Reclutamento
- Robert Debre University Hospital
-
Contatto:
- Julien Hogan, Professor
- Email: julien.hogan2@aphp.fr
-
Investigatore principale:
- Julien Hogan, Professor
-
-
-
-
-
Rome, Italia, 00165
- Non ancora reclutamento
- Ospedale Pediatrico Bambino Gesu
-
Contatto:
- Raffaella Labbadia, MD
- Email: ctc@opbg.net
-
Investigatore principale:
- Raffaella Labbadia, MD
-
-
-
-
-
London, Regno Unito, WC1N 3JH
- Reclutamento
- Great Ormond Street Hospital for Children NHS Foundation Trust
-
Contatto:
- S Marks, MD
-
Investigatore principale:
- S Marks, MD
-
-
-
-
-
Barcelona, Spagna, 08035
- Reclutamento
- Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica
-
Investigatore principale:
- Gema Ariceta, MD
-
Contatto:
- Gema Ariceta, MD
- Email: gema.ariceta@vallhebron.cat
-
Barcelona, Spagna, 08950
- Non ancora reclutamento
- Hospital Sant Joan De Deu Barcelona
-
Contatto:
- Yolanda Calzada, MD
- Email: frecerca.startup@sjd.es
-
Investigatore principale:
- Yolanda Calzada, MD
-
-
-
-
Stockholm County
-
Huddinge, Stockholm County, Svezia, SE-141 86
- Reclutamento
- Karolinska University Hospital
-
Contatto:
- L Wennberg, MD
- Email: Lars.Wennberg@regionstockholm.se
-
Investigatore principale:
- L Wennberg, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Signed Informed Consent obtained from patient/parent/legal guardian/independent witness (depending on patient's age) before any trial-related procedures
- Highly sensitised patient with panel reactive antibodies (PRA) ≥80%
- Male or female patient between the age of 1 to 17 years (up to the day before the 18th birthday) at the time of screening
- Patient with end-stage renal disease (ESRD) and waiting for a renal transplant from a living or deceased donor
- Patient must be transplantable (including size mismatch) at the time of obtaining informed consent for trial participation
- Patients who have previously undergone desensitisation unsuccessfully with plasmapheresis/IVIg/anti-CD20 or have an anti-HLA antibody status deemed too difficult to make a successful desensitisation (judgement based on physicians' previous experience with similar patients)
- Positive crossmatch (XM) test determined by flow cytometry crossmatch (FCXM) and/or complement-dependent cytotoxicity crossmatch (CDCXM) tests against the donor. For the DD patients, if physical XM tests are not practically possible due to lack of time, patients may be included on a virtual crossmatch (vXM) predictive of a positive XM test.
- Willingness and ability to comply with the protocol as judged by the investigator
Exclusion Criteria:
- Previous treatment with imlifidase
- IVIg treatment within 28 days prior to imlifidase treatment
- Desensitisation treatment(s) within 1 month prior to the current transplantation
- Hypersensitivity to the active substance (imlifidase) or to any of the excipients and to other immunosuppressive drugs specified in the protocol
- Ongoing serious infections
- Present, or history of, thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP
- At the time of transplantation: severe other condition requiring treatment and close monitoring e.g. cardiac failure ≥ grade 4 (New York Heart Association), unstable coronary disease, active peripheral vascular disease, proven hypercoagulable conditions/events or oxygen dependent respiratory disease
- Malignancy within 3 years prior to transplantation
- ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted for B recipients)
- Any other reason that, in the view of the investigator, precludes transplantation
- Breast feeding or pregnancy, if applicable
- Woman of fertile age and sexually active without adequate contraceptive measures to avoid pregnancy during the interventional trial period (i.e. up to 6 months after transplantation)
- Suspicion of Covid-19 infection or positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test
- Positive serology for human immunodeficiency virus (HIV)
- Clinical signs of hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), or Epstein Barr virus (EBV) infection
- Donor with positive serology for HIV, HBV, HCV or CMV to a patient with negative serology (mismatch serology). Mismatch serology for EBV in accordance with center specific standard procedures for transplantation of EBV negative recipients and at investigator's discretion.
- Clinically relevant active infection(s) as judged by the investigator
- Tuberculosis or history of tuberculosis
- Use of other investigational agents within 5 terminal elimination half-lives prior to the transplantation
- Contemporaneous participation in medical device studies
- Known mental incapacity or language barriers precluding patients'/parents'/legal guardians' adequate understanding of the informed consent information and the trial activities
- Inability by the judgement of the investigator to participate in the trial for any other reason
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Imlifidase
Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation. |
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatment
Lasso di tempo: From start of imlifidase administration to 24 hours
|
Immunoglobulins (IgG) including donor specific antibodies (DSAs) are rapidly and efficiently cleaved by imlifidase. A conversion of a positive to a negative XM will enable transplantation. |
From start of imlifidase administration to 24 hours
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sopravvivenza del trapianto (morte censurata) fino a 5 anni dopo il trapianto
Lasso di tempo: Da 6 mesi fino a 5 anni
|
Da 6 mesi fino a 5 anni
|
|
|
Sopravvivenza libera da insuccesso dell'innesto fino a 5 anni dopo il trapianto
Lasso di tempo: Da 6 mesi fino a 5 anni
|
Da 6 mesi fino a 5 anni
|
|
|
Sopravvivenza del paziente fino a 5 anni dopo il trapianto
Lasso di tempo: Da 6 mesi fino a 5 anni
|
Da 6 mesi fino a 5 anni
|
|
|
Percentuale di pazienti con dipendenza dalla dialisi fino a 5 anni dopo il trapianto
Lasso di tempo: Da 6 mesi fino a 5 anni
|
Da 6 mesi fino a 5 anni
|
|
|
Renal function up to 5 years after transplantation as assessed by estimated glomerular filtration rate (eGFR)
Lasso di tempo: From pre-dose imlifidase up to 5 years
|
eGFR is a measure of kidney function. Reduced kidney function is characterised by a decreased eGFR value. |
From pre-dose imlifidase up to 5 years
|
|
Renal function up to 5 years after transplantation as assessed by serum/plasma creatinine levels
Lasso di tempo: From pre-dose imlifidase up to 5 years
|
Creatinine is a measure of kidney function. Reduced kidney function is characterised by an increased value. |
From pre-dose imlifidase up to 5 years
|
|
Renal function up to 5 years after transplantation as assessed by serum/plasma cystatin C levels
Lasso di tempo: From pre-dose imlifidase up to 5 years
|
Cystatin C is a measure of kidney function. Reduced kidney function is characterised by an increased value. |
From pre-dose imlifidase up to 5 years
|
|
Renal function up to 5 years after transplantation as assessed by proteinuria
Lasso di tempo: From pre-dose imlifidase up to 5 years
|
Proteinuria (protein/creatinine ratio in urine) is a measure of kidney function. Reduced kidney function is characterised by an increased value. |
From pre-dose imlifidase up to 5 years
|
|
DSA levels up to 5 years after transplantation
Lasso di tempo: From pre-dose imlifidase up to 5 years
|
Donor specific antibodies (DSAs) are antibodies in the recipient directed against the transplanted organ. |
From pre-dose imlifidase up to 5 years
|
|
Frequency of delayed graft function (DGF)
Lasso di tempo: From transplantation up 7 days after transplantation
|
DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019. Frequency of patients having DGF in accordance with this definition will be presented. |
From transplantation up 7 days after transplantation
|
|
Length of DGF
Lasso di tempo: From transplantation up 7 days after transplantation
|
DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019. The duration of DGFs in accordance with this definition will be presented. |
From transplantation up 7 days after transplantation
|
|
Imlifidase Pharmacokinetics (AUC)
Lasso di tempo: From pre-dose imlifidase up to Day 15
|
AUC = Area under the imlifidase plasma concentration versus time curve. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (Cmax)
Lasso di tempo: From pre-dose imlifidase up to Day 15
|
Cmax = Maximum observed plasma concentration of imlifidase following dosing. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (tmax)
Lasso di tempo: From pre-dose imlifidase up to Day 15
|
tmax = Time point for maximum observed plasma concentration of imlifidase following dosing |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (t1/2)
Lasso di tempo: From pre-dose imlifidase up to Day 15
|
t1/2 = Terminal half-life of imlifidase. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (CL)
Lasso di tempo: From pre-dose imlifidase up to Day 15
|
CL = Clearance of imlifidase. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (Vz)
Lasso di tempo: From pre-dose imlifidase up to Day 15
|
Vz = Volume of distribution during the elimination phase |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacodynamic (PD) profile up to 9 days after imlifidase treatment
Lasso di tempo: From pre-dose imlifidase up to Day 10
|
PD is assessed as serum concentrations of intact IgG and its fractions following infusion. |
From pre-dose imlifidase up to Day 10
|
|
Immunogenicity profile of imlifidase up to 5 years after imlifidase treatment
Lasso di tempo: From pre-dose imlifidase up to 5 years
|
Immunogenicity is assessed as serum concentration of anti-imlifidase IgG (ADA). |
From pre-dose imlifidase up to 5 years
|
|
Proportion of patients with biopsy- and serology (DSA)-confirmed AMR up to 5 years after transplantation
Lasso di tempo: From transplantation up to 5 years
|
Banff scores (Loupy et al. 2020) will be used for biopsy evaluation. |
From transplantation up to 5 years
|
|
Proportion of patients with biopsy confirmed cell-mediated rejection (CMR) up to 5 years after transplantation
Lasso di tempo: From transplantation up to 5 years
|
Banff scores (Loupy et al. 2020) will be used for biopsy evaluation. |
From transplantation up to 5 years
|
Altre misure di risultato
Misura del risultato |
Lasso di tempo |
|---|---|
|
Sicurezza valutata come percentuale di pazienti con reazioni correlate all'infusione entro 48 ore dall'infusione di imlifidase
Lasso di tempo: Dall'inizio dell'infusione di imlifidase fino a 48 ore
|
Dall'inizio dell'infusione di imlifidase fino a 48 ore
|
|
Sicurezza valutata come percentuale di pazienti con infezioni gravi o gravi entro 30 giorni dopo il trattamento con imlifidasi
Lasso di tempo: Dall'inizio dell'infusione di imlifidasi fino a 30 giorni
|
Dall'inizio dell'infusione di imlifidasi fino a 30 giorni
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Clinical Operations, Hansa Biopharma AB
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Processi patologici
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattia cronica
- Attributi della malattia
- Insufficienza renale
- Insufficienza renale cronica
- Condizioni patologiche, segni e sintomi
- Insufficienza renale cronica
- Proteina simile a Mac-1, Streptococcus
Altri numeri di identificazione dello studio
- 20-HMedIdes-21
- 2022-500230-28-00 (Altro identificatore: EU Trial Number)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .